| | |
Radhieka Pandeya 01:15 AM | June 04,2009
When it was founded in 1937, the then Ranbaxy and Co.’s first business was reselling drugs made by Japanese firm A Shiniogi. Seven decades later, the Singh family sold out to a Japanese firm
|
|
Radhieka Pandeya 11:59 PM | May 25,2009
Ranbaxy is also slated to start formulating a significant portion of AstraZeneca’s US supply of Nexium from May 2010
|
|
Radhieka Pandeya 11:39 PM | April 26,2009
Focus shifts away from volumes as European revenue for March quarter contracts 31%; trouble breaking even
|
|
C.H. Unnikrishnan and P.R. Sanjai 03:09 PM | September 21,2008
The promoters have renamed Fortis Healthworld Ltd, SRL Ranbaxy Ltd and Ran Air Services Ltd, which are engaged in drug retail, diagnostics and air travel, under the Religare brand
|
|
Breakingviews.com | Martin Hutchinson 12:10 AM | June 13,2008
This reduced Ranbaxy’s dependence on the US, which had accounted for 45% of its sales, but left the company overleveraged
|
|
Mark To Market | Mobis Philipose 01:24 AM | June 12,2008
A shareholder couldn’t ask for more, especially given the risks associated with the generics segment of the pharmaceuticals business
|
|
Ravi Krishnan 01:00 AM | June 12,2008
Daiichi Sankyo will buy out Singh family’s 35% stake at Rs737 a share, a 31.4% premium over Tuesday’s closing price
|
|
12:56 AM | June 12,2008
Malvinder Singh has come of age and opened a window of opportunity that is both modern and necessary
|
|
Josey Puliyenthuruthel and Krish Raghav 12:37 AM | June 12,2008
Ranbaxy Labs’ chief executive Malvinder Singh said the deal would be transformational for the global pharmaceutical industry
|
|
C.H. Unnikrishnan 11:53 PM | June 11,2008
Capability to produce generics at a fraction of the costs in developed markets will see Indian cos’ valuations shoot up
|
|
Puneet Wadhwa and Taneesha Kulshrestha 03:33 PM | June 11,2008
Ranbaxy valued at $8.8 billion with Daiichi paying Rs737 per share at 70% premium to market cap
|
|
12:30 PM | May 18,2008
Five Indians figure on the London-based World Pharmaceutical Frontiers’ magazine’s list of 40 most influential people in the global pharma industry
|
|
Bhuma Shrivastava 12:36 AM | November 15,2007
Ranbaxy spent a total of Rs639.3 crore on research in 2005 and Rs483.8 crore in 2006.
|
|
Bhuma Shrivastava 01:06 AM | October 19,2007
Gurgaon-based drug maker announces that it will hive off research unit into a separate firm
|
|
02:35 PM | October 12,2007
Over 78 lakh Zenotech shares will be bought from existing promoters, 55 lakh shares will be issued to Ranbaxy on preferential allotment
|
|